Analyst consensus rating
ImmunityBio Analyst Rating: Strong Buy
Direct answer
ImmunityBio's consensus rating is Strong Buy.
4 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $13.75.
Forecast evidence checked October 15, 2026.
Get free ImmunityBio email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $9.91
- Average price target
- $13.75
- High price target
- $16.00
- Low price target
- $12.00
- Low target gap
- +21.1%
- Target upside
- +38.7%
- High target gap
- +61.5%
- Target range width
- 40.4%
- Consensus rating
- Strong Buy
- Analysts
- 4
- Evidence date
- October 15, 2026
- Valid through
- October 22, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for ImmunityBio?
ImmunityBio has a verified Strong Buy consensus. The same dataset has an average price target of $13.75.
How far are ImmunityBio's low and high targets from the recorded price?
The low target implies +21.1%, while the high target implies +61.5%.
How many analysts are included in ImmunityBio's consensus?
The verified consensus includes 4 analysts.
How is ImmunityBio's target upside or downside calculated?
The average target of $13.75 is divided by the recorded price of $9.91, then one is subtracted to produce +38.7%. This does not guarantee a future return.
When was ImmunityBio's analyst forecast verified?
The data was verified on 2026-10-15. The dataset is valid through 2026-10-22.